Abstract
1.Abstract1.1BackgroundArtemisinin-based treatments (ACTs) are the first therapy currently used to treat malaria produced byPlasmodium falciparum. However, in recent years increasing evidence shows that some strains ofP. falciparumare less susceptible to ACT in the Southeast Asian region.1.2Materials & MethodsA data reanalysis of several omics approaches currently available about parasites ofP. falciparumthat have some degree of resistance to ACT was carried out. The data used was from transcriptomics and metabolomics studies. One mitochondrial carrier of the parasite possibly involved in the mechanisms of tolerance to oxidative stress was modelled and subjected to molecular dockings with citrate and oxoglutarate.1.3ResultsAn increase in glutathione production was detected, changing the direction of the flux of metabolites in the tricarboxylic acid cycle, and boosting glucose consumed. The models of the mitochondrial carrier, called PfCOCP, show that it may be important in transporting citrate and oxoglutarate from the mitochondrial matrix to cytosol. If so, it may allow the parasite to tolerate the oxidative stress produced by artemisinin.1.4ConclusionsThisin-silicoanalysis shows thatP. falciparummay tolerate the artemisinin’s oxidative stress through metabolic changes not reported before, showing the need for further research on the many metabolic aspects linked to this phenotype.
Publisher
Cold Spring Harbor Laboratory